Literature DB >> 22782668

Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients.

Han-Bo Le1, Wang-Yu Zhu, Dong-Dong Chen, Jian-Ying He, Yan-Yan Huang, Xiao-Guang Liu, Yong-Kui Zhang.   

Abstract

Although circulating microRNAs (miRNAs) were frequently detected in sera of cancer patients, there is still a lack of analysis of the dynamic changes of miRNAs expression in sera of pre- and post-operative lung carcinoma patients. Thus, we conducted quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to examine the expression of four miRNAs (miR-21, miR-205, miR-30d, and miR-24) in the sera of a set of 82 pre-operative lung carcinoma patients and paired 10 days post-operative patients, as well as in 50 normal volunteers. We showed that, compared to that in normal volunteers, the expression of miR-21, miR-205, miR-30d, and miR-24 was increased in lung cancer sera samples, as well as in sera of early stage lung cancer patients according to their clinical-pathological characteristics. The area under roc curves (AUCs) for levels of miR-21, miR-205, miR-30d, and miR-24 in sera were significantly higher than those for Carcinoma embryonic antigen (CEA) (P < 0.05), whereas the AUC for combination of serum levels of miRNA with serum CEA showed no significant difference from that for serum levels of miRNAs only (P > 0.05). The expression levels of miR-21 and miR-24 were significantly decreased in post-operative sera compared with levels in paired pre-operative sera (P = 0.0004 and <0.0001, respectively). In addition, high expressions of miR-21 and miR-30d in pre-operative sera were independently correlated with shorter overall survival in lung cancer patients (log-rank test: P = 0.0498, 0.0019). In summary, our results suggest that miR-21, miR-205, miR-30d, and miR-24 may serve as potential novel non-invasive biomarkers for diagnosis of lung cancer. In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22782668     DOI: 10.1007/s12032-012-0303-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  30 in total

1.  Define relative incomplete resection by highest mediastinal lymph node metastasis for non-small cell lung cancers: rationale based on prognosis analysis.

Authors:  Hui Zheng; Xue-fei Hu; Ge-ning Jiang; Wen Gao; Sen Jiang; Hui-kang Xie; Jia-an Ding; Chang Chen
Journal:  Lung Cancer       Date:  2010-11-13       Impact factor: 5.705

2.  Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status.

Authors:  Xuan Zhou; Yu Ren; Lynette Moore; Mei Mei; Yongping You; Peng Xu; Baoli Wang; Guangxiu Wang; Zhifan Jia; Peiyu Pu; Wei Zhang; Chunsheng Kang
Journal:  Lab Invest       Date:  2010-01-04       Impact factor: 5.662

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis.

Authors:  Andreas Keller; Petra Leidinger; Randi Gislefoss; Aage Haugen; Hilde Langseth; Peer Staehler; Hans-Peter Lenhof; Eckart Meese
Journal:  RNA Biol       Date:  2011-05-01       Impact factor: 4.652

5.  Plasma microRNAs as novel biomarkers for early detection of lung cancer.

Authors:  Dali Zheng; Shadi Haddadin; Yong Wang; Li-Qun Gu; Michael C Perry; Carl E Freter; Michael X Wang
Journal:  Int J Clin Exp Pathol       Date:  2011-08-08

6.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

8.  miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells.

Authors:  Wenming Qin; Yi Shi; Botao Zhao; Chengguo Yao; Li Jin; Jiexian Ma; Youxin Jin
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

9.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

10.  Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions.

Authors:  Li Xie; Xi Chen; Lifeng Wang; Xiaoping Qian; Tingting Wang; Jia Wei; Lixia Yu; Yitao Ding; Chenyu Zhang; Baorui Liu
Journal:  BMC Cancer       Date:  2010-10-28       Impact factor: 4.430

View more
  62 in total

1.  The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.

Authors:  Wang-Yang Chen; Xiao-Juan Zhao; Zhi-Fu Yu; Fu-Lan Hu; Yu-Peng Liu; Bin-Bin Cui; Xin-Shu Dong; Ya-Shuang Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis.

Authors:  Wen-Jie He; Wen-Hui Li; Bo Jiang; Yu-Feng Wang; Yao-Xiong Xia; Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer.

Authors:  Guibin Zhao; Lijie Liu; Tianshu Zhao; Shoude Jin; Sibo Jiang; Shouqiang Cao; Jingquan Han; Yanzhong Xin; Qing Dong; Xian Liu; Jian Cui
Journal:  Tumour Biol       Date:  2015-03-01

Review 4.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

5.  The expression and clinical significance of serum miR-205 for breast cancer and its role in detection of human cancers.

Authors:  Hui Zhang; Baowei Li; Hebao Zhao; Jin Chang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis.

Authors:  Ke-Cheng Zhang; Hong-Qing Xi; Jian-Xin Cui; Wei-Song Shen; Ji-Yang Li; Bo Wei; Lin Chen
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

7.  microRNA-664 enhances proliferation, migration and invasion of lung cancer cells.

Authors:  Xinhai Zhu; Sheng Ju; Feng Yuan; Guoping Chen; Yue Shu; Chuanchuan Li; Yanhui Xu; Jing Luo; Lilong Xia
Journal:  Exp Ther Med       Date:  2017-05-05       Impact factor: 2.447

8.  Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.

Authors:  Fan-Long Meng; Wei Wang; Wei-Dong Jia
Journal:  Med Oncol       Date:  2014-08-17       Impact factor: 3.064

Review 9.  Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.

Authors:  Blanca Ortiz-Quintero
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

Review 10.  Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.

Authors:  Viswam S Nair; Colin C Pritchard; Muneesh Tewari; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.